In connection with the consummation of the Merger on November 2, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) notified Nasdaq of the completion of the Merger and requested that Nasdaq (i) suspend trading of the Supernus Common Stock, effective prior to the opening of trading on November 2, 2026, and (ii) file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of the Supernus Common Stock from Nasdaq and the deregistration of the Supernus Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Following the effectiveness of such Form 25, the Company intends to file with the SEC a certification on Form 15 requesting the deregistration of the Supernus Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act. As a result of the Merger, the Supernus Common Stock will no longer be listed on any national securities exchange.
|
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company’s portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), Parkinson’s disease, epilepsy, migraine, postpartum depression, and cervical dystonia. Key commercial products include Qelbree for ADHD, GOCOVRI and APOKYN for Parkinson’s disease, Trokendi XR and Oxtellar XR for epilepsy and migraine, and ZURZUVAE for postpartum depression. Supernus markets its products in the United States through its own specialty sales force and collaborates with partners such as Biogen and Shionogi for international commercialization. The company was incorporated in 2005 following the acquisition of assets from Shire Laboratories, Inc., and completed the acquisition of Sage Therapeutics in July 2025. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage supernus.com |
| Sector Healthcare | IR page supernus.com/Investors | |
|
Tags
neurology, psychiatry, adhd, parkinsons disease, epilepsy, migraine, postpartum depression, central nervous system, specialty pharmaceuticals, Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, Sage Therapeutics, Biogen, Shionogi
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 2.709B |
| Market cap (USD) | $ 2.709B |
| P/E | 33.22 |
| PEG | — |
| P/BV | 2.55 |
| P/S | 3.13 |
| P/OCF | 30.73 |
| P/FCF | 31.16 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -3.7% |
| ROI | -4.0% |
| ROIC | -4.8% |
| Profit margin | -5.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 41 |
| Quality score | -41.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 718.952M | 661.817M | 607.521M | 667.238M | 579.775M | 520.397M | 392.755M | 408.897M | 302.238M | 215.003M | 144.427M | 122.045M | 12.019M | 1.48M | 803K |
| Net profit | -38.55M | 73.865M | 1.316M | 60.711M | 53.424M | 126.95M | 113.056M | 110.993M | 57.284M | 91.221M | 14.016M | 19.871M | -92.273M | -46.284M | 53.815M |
| Free cash flow | 45.993M | 171.226M | 110.534M | 116.414M | 125.082M | 134.95M | 140.393M | 128.142M | 112.611M | 65.209M | 30.019M | 7.14M | -59.595M | -47.952M | -36.87M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 49.7 | 36.16 | 28.94 | 35.67 | 29.16 | 25.16 | 23.72 | 33.22 | 39.85 | 25.25 | 13.44 | 8.3 | 7.54 | 7.18 | — |
| Price performance 12m | 0.37 | 0.25 | -0.19 | 0.22 | 0.16 | 0.06 | -0.29 | -0.17 | 0.58 | 0.88 | 0.62 | 0.1 | 0.05 | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
November 2, 2026 at 9:18 AM EST
-
Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
-
Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
-
Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.
Supernus, Inc. Creates Immediate Scale and Expanded Capabilities
-
A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE®, Qelbree®, GOCOVRI®, ONAPGO®, and ZURZUVAE® – that provide a durable foundation for long-term revenue expansion.
-
Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.
“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”
Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, "This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value."
The Merger and Transaction Details Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.
Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.
Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.
Leadership and Governance Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company's Board of Directors has a total of eight directors, including four directors from each of the legacy companies.
Advisors Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.
Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.
Additional information about the transaction can be found on the Supernus website, which is listed below.
About Supernus, Inc. Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.
Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Subject Company: Supernus Pharmaceuticals, Inc.
Commission File No.: 001-35518
Date: October 29, 2026
Exhibit 99.1
Supernus Announces Third Quarter 2026 Financial Results
•Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.
•Combined revenues of the Company's four growth products increased to $192.2 million in the third quarter 2026, representing an increase of 29% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® , GOCOVRI®, ZURZUVAE®, and ONAPGO™.
•Received orphan-drug exclusive approval for ONAPGO and submitted an sNDA to the FDA to add a second supplier.
•Merger with Indivior Pharmaceuticals, Inc. (Indivior) expected to close on November 2, 2026.
ROCKVILLE, Md., October 29, 2026 – Supernus Pharmaceuticals, Inc.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Nov 2, 2026 | Acquired by | Acquired by Supernus, Inc. (CIK 1625297). |
ETFs Holding Supernus Pharmaceuticals, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AFSC | 2.25% | 5,061 | $ 225.872K | Jul 31, 2026 |
| GSC | 0.54% | 33,901 | $ 1.499M | Aug 31, 2026 |
| SQLV | 0.38% | 2,370 | $ 110.229K | Jun 30, 2026 |
| ESSC | 0.26% | 2,064 | $ 92.116K | Jul 31, 2026 |
| FESM | 0.23% | 281,390 | $ 13.087M | Jun 30, 2026 |
| OASC | 0.13% | 2,865 | $ 126.662K | Aug 31, 2026 |
| PSC | 0.13% | 67,051 | $ 3.119M | Jun 30, 2026 |
| FSEV | 0.12% | 170 | $ 7,906.70 | Jun 30, 2026 |
| RESM | 0.12% | 93 | $ 4,325.43 | Jun 30, 2026 |
| FSCC | 0.11% | 9,403 | $ 415.707K | Aug 31, 2026 |
| FEAC | 0.04% | 226 | $ 10.511K | Jun 30, 2026 |
| MSSM | 0.01% | 2,028 | $ 89.658K | Aug 31, 2026 |
| EBI | 0.00% | 439 | $ 19.408K | Aug 31, 2026 |